Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07051655 · ClinicalTrials.gov registry record · NA
The Effects of Exogenous Ketones on Cognitive Function
A NA study of Placebo - Control and Ketone Monoester, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT07051655: Recruiting NA study of Placebo - Control and Ketone Monoester, sponsored by University of Alabama at Birmingham.
NCT07051655 is a NA study of Placebo - Control and Ketone Monoester that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07051655, a NA study of Placebo - Control and Ketone Monoester, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the acute effects of exogenous ketone monoester (KME) supplementation on cognitive function in three groups of adults aged 19-55 years: (1) obese, sedentary individuals; (2) lean, sedentary individuals; and (3) lean individuals who engage in regular physical activity (e.g., collegiate or amateur athletes). The main questions it aims to answer are to: * Assess the effects of acute KME supplementation versus placebo on cognitive, sensorimotor, and functional outcomes within groups. * Compare cognitive performance across the three groups. The primary outcome is cognitive performance assessed using the NIH Toolbox Cognition Battery. Secondary Outcomes include sensorimotor performance, measured using the Senaptec Sensory System, and driving performance, assessed with a driving simulator.
Primary Outcome
Cognitive function will be assessed using the NIH Toolbox Cognition Battery, administered on an iPad. \- Dimensional Change Card Sort Test - Measures executive function and cognitive flexibility by assessing the ability to switch between mental rules.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Ketone Monoester (KE)
Study Locations (1)
Alabama
- 916 Building - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-12-01 |
| Est. Completion | 2026-04 |
| Phase | NA |
What NCT07051655 shows while recruiting
NCT07051655 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Placebo - Control appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07051655 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT07051655 about?
NCT07051655 is a clinical study titled "The Effects of Exogenous Ketones on Cognitive Function". The purpose of this study is to evaluate the acute effects of exogenous ketone monoester (KME) supplementation on cognitive function in three groups of adults aged 19-55 years: (1) obese, sedentary individuals; (2) lean, sedentary individuals; and (3) lean individuals who engage in regular physical ...
What is the current status of trial NCT07051655?
This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2025-12-01. Estimated completion is 2026-04.
What conditions does trial NCT07051655 study?
This clinical trial studies the following conditions: Placebo - Control, Ketone Monoester.
What interventions are being tested in trial NCT07051655?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Ketone Monoester (KE) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07051655?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07051655 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Placebo - Control
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07051655's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI